🚀
Enjoy a 7-Day Free Trial Thru Dec 08, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Canadian Insider
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Drug Manufacturers
Novo Nordisk AS (OCSE:NOVO B)
News
Novo Nordisk AS - Class B
3
OCSE
:NOVO B (Denmark) Â
Class B
kr 757.30
(+1.3%)
Nov 29
P/E:
35.72
P/B:
27.97
Market Cap:
kr 3.36T
($ 477.14B)
Enterprise V:
kr 3.35T
($ 474.60B)
Volume:
4.28M
Avg Vol (2M):
3.04M
Warning! GuruFocus detected 1 Severe warning sign with NOVO B.
Try a 7-Day Free Trial
to check it out.
Trade In:
Volume:
4.28M
Market Cap kr:
3.36T
Market Cap $:
477.14B
PE Ratio:
35.72
Avg Vol (2M):
3.04M
Enterprise Value kr:
3.35T
Enterprise Value $:
474.60B
PB Ratio:
27.97
Alerts
Website
Sources
Stock PDF
Dataset
Financial Download
Manual of Stocksâ„¢
Compare
0
Summary
30-Y Financials
Estimates
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
Novo Nordisk AS (OCSE:NOVO B) Stock News, Headlines & Updates
Novo Nordisk AS Stock News from GuruFocus
Total 29
1
Nov 29, 2024
European Pharma Giants Face Challenges Amid U.S. Policy Shifts
GuruFocus News
•
2:30am
Nov 27, 2024
Biden's Move to Combat Obesity Helped Eli Lily and Novo Nordisk Shares Higher
ShantiPutri
•
12:39am
Nov 22, 2024
Novo Nordisk (NVO) Partners with Ypsomed for Next-Gen Obesity Drug Delivery
GuruFocus News
•
7:50am
Nov 21, 2024
Novo Nordisk AS (NVO) Shares Down 3.01% on Nov 21
GuruFocus News
•
10:23am
Nov 17, 2024
Novo Nordisk's Ozempic Launches in China for Obesity Management
GuruFocus News
•
8:10am
Nov 16, 2024
Novo Nordisk AS (NVO) Stock Price Down 3.4% on Nov 16
GuruFocus News
•
4:54am
Nov 11, 2024
Novo Nordisk's (NVO) CagriSema Expected to Outperform Rivals in Weight Loss
GuruFocus News
•
1:11pm
Nov 08, 2024
Q3 2024 Novo Nordisk A/S Earnings Presentation (London-Based Investors) Transcript
GuruFocus News
•
11:19pm
Nov 07, 2024
Novo Nordisk AS (NVO) Q3 2024 Earnings Call Highlights: Robust Sales Growth and Strategic Developments
GuruFocus News
•
1:06am
Q3 2024 Novo Nordisk A/S Earnings Call Transcript
GuruFocus News
•
11:07pm
Nov 06, 2024
Novo Nordisk (NVO) Raises Concerns Over Safety of Semaglutide Copies
GuruFocus News
•
3:31pm
Novo Nordisk Dominates Obesity Market as Wegovy Sales Soar 76%
Khac Phu Nguyen
•
10:29am
Earnings To Watch: Novo Nordisk AS (OCSE:NOVO B) Reports Q3 2024 Result
GuruFocus News
•
6:01am
Nov 05, 2024
Earnings To Watch: Novo Nordisk AS (OCSE:NOVO B) Reports Q3 2024 Result
GuruFocus News
•
6:35am
Novo Nordisk Secures License for Ascendis Pharma's Obesity Drug Technology
Faizan Farooque
•
5:31am
Nov 04, 2024
Novo Nordisk's CagriSema: A Potential Game-Changer in Weight Loss Medication
GuruFocus News
•
9:11am
Nov 01, 2024
NVO Reports Positive Phase III Trial Results for Semaglutide in MASH Treatment
GuruFocus News
•
2:10pm
Oct 31, 2024
Wegovy and Ozempic Gain Full Availability in U.S.
GuruFocus News
•
12:31am
Oct 29, 2024
Weight Loss Drug Market: NVO's Stock to Rebound Amid Competition with LLY
GuruFocus News
•
7:51am
Oct 24, 2024
Novo Nordisk (NVO) Challenges Compounded Semaglutide Production Over Safety Concerns
GuruFocus News
•
10:10pm
Oct 21, 2024
Novo Nordisk's Rybelsus Sets New Standard: 14% Cut in Cardiovascular Risks for Diabetics
Khac Phu Nguyen
•
10:30am
NVO Breakthrough: Rybelsus Reduces Heart Attack and Stroke Risk in Study
GuruFocus News
•
8:30am
Oct 18, 2024
NVO Faces Scrutiny Over Catalent Acquisition Amid Competition Concerns
GuruFocus News
•
7:32am
Oct 09, 2024
Novo Nordisk AS (NVO) Q2 2024 Earnings Call Highlights: Robust Sales Growth and Strategic Advancements
GuruFocus News
•
3:26pm
Q2 2024 Novo Nordisk A/S Earnings Call (London-Based Investors) Transcript
GuruFocus News
•
1:37pm
Sep 30, 2024
Invesco EQV European Equity Fund Bolsters Position in Teva Pharmaceutical with a 1.25% Portfolio Stake
GuruFocus Research
•
11:01am
NVO Leads Denmark's Economic Surge with Pharmaceutical Growth
GuruFocus Research
•
9:33am
European Healthcare Stocks Face Decline Over Novo Nordisk and AstraZeneca Updates
GuruFocus Research
•
9:32am
Sep 27, 2024
Novo Nordisk (NVO) Faces Slump Amid Weaker Than Expected Wegovy Sales
GuruFocus Research
•
11:32am
Total 29
1
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news